Pulmonx Corporation (LUNG)

Market Cap	68.64M -80.0%
Revenue (ttm)	90.50M +8.0%
Net Income	-54.00M
EPS	-1.33
Shares Out	42.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	270,629
Open	1.650
Previous Close	1.610
Day's Range	1.595 - 1.650
52-Week Range	1.310 - 8.120
Beta	0.11
Analysts	Buy
Price Target	5.38 (+231.08%)
Earnings Date	Mar 4, 2026

About LUNG

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with mult...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 1, 2020
• Employees: 291
• Stock Exchange: NASDAQ
• Ticker Symbol: LUNG
• Website: https://pulmonx.com

Financial Performance

In 2025, Pulmonx's revenue was $90.50 million, an increase of 8.01% compared to the previous year's $83.79 million. Losses were -$54.00 million, -4.24% less than in 2024.

Analyst Summary

According to 7 analysts, the average rating for LUNG stock is "Buy." The 12-month stock price target is $5.38, which is an increase of 231.08% from the latest price.

Price Target

$5.38

(231.08% upside)

Analyst Consensus: Buy